.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Dow
Deloitte
Medtronic
McKesson
Fish and Richardson
Harvard Business School
Queensland Health
Julphar
Cerilliant

Generated: December 12, 2017

DrugPatentWatch Database Preview

JADENU Drug Profile

« Back to Dashboard

When do Jadenu patents expire, and when can generic versions of Jadenu launch?

Jadenu is a drug marketed by Novartis Pharms Corp and is included in two NDAs. There are three patents protecting this drug and three Paragraph IV challenges.

This drug has seventy-four patent family members in forty-six countries and nine supplementary protection certificates in eight countries.

The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferasirox profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-001Mar 30, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-002Mar 30, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-001Mar 30, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-003Mar 30, 2015RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-002Mar 30, 2015RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Novartis Pharms CorpJADENU SPRINKLEdeferasiroxGRANULE;ORAL207968-002May 18, 2017RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-001Mar 30, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-001Mar 30, 2015RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-002Mar 30, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-002Mar 30, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: JADENU

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-001Mar 30, 2015► Subscribe► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-003Mar 30, 2015► Subscribe► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-002Mar 30, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for JADENU

Drugname Dosage Strength RLD Submissiondate
deferasiroxTablets180 mgJadenu4/28/2016
deferasiroxTablets90 mg and 360 mgJadenu10/19/2015
deferasiroxTablets180 mgJadenu10/23/2015

Non-Orange Book Patents for Tradename: JADENU

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,723,742 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: JADENU

Country Document Number Estimated Expiration
Uruguay35367► Subscribe
Slovenia914118► Subscribe
Tunisia2015000393► Subscribe
Australia718037► Subscribe
Dominican RepublicP2015000220► Subscribe
African Intellectual Property Organization (OAPI)10946► Subscribe
Taiwan533205► Subscribe
South Korea20000022222► Subscribe
African Regional IP Organization (ARIPO)9801407► Subscribe
Israel240797► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: JADENU

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0914118/01Switzerland► SubscribePRODUCT NAME: DEFERASIROX; REGISTRATION NUMBER/DATE: SWISSMEDIC 57466 03.11.2005
2007001Lithuania► SubscribePRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006 08 28, EU/1/06/356/002 2006 08 28, EU/1/06/356/003 2006 08 28, EU/1/06/356/004 2006 08 28, EU/1/06/356/005 2006 08 28, EU/1/06/356/00 20060828
0Finland► Subscribe
2006 00035Denmark► Subscribe
0248Netherlands► Subscribe300248, 20170624, EXPIRES: 20210827
C0049France► SubscribePRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828
C/GB07/002United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021.
2007001,C0914118Lithuania► SubscribePRODUCT NAME: DEFERASIROXUM; REGISTRATION NO/DATE: EU/1/06/356/001 2006-08-28, EU/1/06/356/002 2006-08-28, EU/1/06/356/003 2006-08-28, EU/1/06/356/004 2006-08-28, EU/1/06/356/005 2006-08-28, EU/1/06/356/00 20060828
C 035/2006Ireland► SubscribeSPC 035/2006: 20070528, EXPIRES: 20210827
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Deloitte
Covington
McKinsey
McKesson
Dow
Boehringer Ingelheim
Julphar
Mallinckrodt
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot